Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.
Amyloidosis comprises a unique group of diseases that share in common the extracellular deposition of insoluble fibrillar proteins in organs and tissues. Cardiovascular amyloidosis can be primary, a part of systemic amyloidosis, or a result of chronic systemic diseases elsewhere in the body. The most common presentations are congestive heart failure-mainly a restrictive infiltrative pattern--and conduction system disturbances. Recent developments in imaging techniques and extracardiac tissue sampling have minimized the need for invasive endomyocardial biopsy for amyloidosis. Despite advances in treatment, the prognosis for patients with amyloidosis is still poor and depends on the underlying disease type. Herein, we present new insights and recent advances in cardiovascular amyloidosis.
Hassan
Walid
W
Department of Cardiovascular Disease, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. hassanw@kfshrc.edu.sa
Al-Sergani
Hani
H
Mourad
Walid
W
Tabbaa
Rashed
R
D000682:Amyloid / Q000378:metabolism; D000686:Amyloidosis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D028226:Amyloidosis, Familial / Q000145:classification; D009202:Cardiomyopathies / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D002313:Cardiomyopathy, Restrictive / Q000175:diagnosis; D004452:Echocardiography; D004562:Electrocardiography; D006801:Humans; D009206:Myocardium / Q000473:pathology; D011379:Prognosis
D000682:Amyloid